Gout, a painful form of inflammatory arthritis, is projected to rise significantly over the next 25 years, driven by aging populations, obesity, and lifestyle factors. In the U.S. alone, over 9 million people have been diagnosed with gout, and an additional 44 million people have uric acid levels above the normal range, putting them at risk. Current treatments, primarily oral xanthine oxidase inhibitors, can cause severe gastrointestinal issues, kidney toxicity, and cardiovascular risks, and they carry boxed warnings. These side effects often lead to poor patient adherence, leaving a significant unmet need for better options.
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company, is developing XORLO™, a proprietary formulation of oxypurinol designed to address these challenges. According to XORTX, XORLO utilizes a liposomal delivery system that significantly increases oral absorption, allowing for effective uric acid reduction at lower, better-tolerated doses. This approach minimizes the toxic-level exposure and severe gastrointestinal side effects associated with high-dose traditional therapies. The company recently announcing the launch of drug material and tablet manufacturing to support a planned two-part clinical study, XRX-OXY-102.
The study is based on positive prior clinical results and discussions with the FDA. Contract production of pure oxypurinol drug substance has begun, and XORTX is working with its contract manufacturing partner toward making commercial drug batches. The company is also working toward a new drug application submission to the FDA for XORLO. It has prepared a new Investigational New Drug (IND) application for submission in the fourth quarter of 2026 and intends to file a New Drug Application (NDA) once the two-part clinical trial is complete. XORTX is targeting an NDA submission in about one year and expects XORLO to have a market opportunity of $700 million annually.
“Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program,” said Allen Davidoff, Co-CEO of XORTX. “It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option.”
For leaders in biotech and healthcare, XORTX's progress highlights the potential for innovative drug delivery systems to improve treatment adherence and outcomes in chronic diseases. If successful, XORLO could capture a significant share of the growing gout market, which is expected to expand as prevalence rises. The company's focus on meeting regulatory milestones and scaling manufacturing demonstrates a strategic approach to commercialization. As the population ages and gout rates climb, effective and well-tolerated therapies will be crucial for reducing healthcare costs and improving quality of life. This content was originally published on Benzinga. View the original release on www.newmediawire.com.
